P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS

P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS

Bibliographic Details
Main Authors:	K. Geissler, Z. Koristek, T. Bernal del Castillo, J. Novák, G. Rodriguez Macias, S. K. Metzelder, A. Illes, A. Nagy, J. Mayer, M. Arnan, M.-M. Keating, J. Krauter, M. Lunghi, N. Stefano Fracchiolla, U. Platzbecker, V. Santini, Y. Sano, A. Oganesian, H. Keer, M. Lübbert
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845180.87968.2a

Similar Items

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
by: Anne Sophie Kubasch, et al.
Published: (2018-05-01)

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
by: Lien Provez, et al.
Published: (2023-01-01)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
by: Nora Rebeka Javorniczky, et al.
Published: (2023-11-01)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
by: Lia Gore, et al.
Published: (2017-10-01)

TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
by: Eleonora De Bellis, et al.
Published: (2017-07-01)

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML
by: Jacobien Hilberink, et al.
Published: (2023-08-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
by: Hongjiao Li, et al.
Published: (2023-09-01)

P471: ERYTHROID/MEGAKARYOCYTIC DIFFERENTIATION BIAS IN BONE MARROW OF AML/MDS PATIENTS AFTER DECITABINE TREATMENT
by: F. Tiso, et al.
Published: (2022-06-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
by: Brian A. Jonas, et al.
Published: (2023-01-01)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
by: Syed Ehsanullah, et al.
Published: (2023-01-01)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
by: Jacobien R. Hilberink, et al.
Published: (2023-06-01)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
by: Nicholas J. Short, et al.
Published: (2022-01-01)

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
by: Ruth Meier, et al.
Published: (2022-08-01)

Absence of early platelet increment in healthy mice during decitabine treatment
by: Juliane Baumann, et al.
Published: (2022-12-01)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
by: Soon Khai Low, et al.
Published: (2022-01-01)

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
by: Thomas Oellerich, et al.
Published: (2019-08-01)

P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
by: Domenico Russo, et al.
Published: (2023-08-01)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
by: Danielle Hammond, et al.
Published: (2023-09-01)

Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma
by: Parunya Chaiyawat, et al.
Published: (2020-12-01)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
by: Federica Lessi, et al.
Published: (2021-08-01)

Authors' List [pp. 573-586]
by: Hystrix Editor
Published: (2008-05-01)

NK-CELLS TRAFFIC TO THE BONE MARROW AS A POTENTIAL IMMUNOLOGICAL MECHANISM OF ACTION OF HYPOMETHYLATING AGENTS FOR HIGH-RISK MDS AND AML
by: J. Hong, et al.
Published: (2024-01-01)

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
by: Taichun Qin, et al.
Published: (2011-01-01)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
by: Yifan Liu, et al.
Published: (2023-11-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
by: M. Lübbert, et al.
Published: (2022-06-01)

P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)
by: Katja Sockel, et al.
Published: (2023-08-01)

EAL573 - KEJURUTERAAN LALU LINTAS. APRIL 2003
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2003)

CIT 573 - FINANCIAL PLANNING & MANAGEMENT NOV 2008
by: PPSKOM, Pusat Pengajian Sains Komputer
Published: (2008)

CIT573 – Financial Planning & Management June 2018
by: PPSKOM, Pusat Pengajian Sains Komputer
Published: (2018)

CIT573 – Financial Planning and Management June 2019
by: PPSKOM, Pusat Pengajian Sains Komputer
Published: (2019)

Saving the “Undoomed Man” In Beowulf (572b-573)
by: Anderson Salena Sampson
Published: (2015-01-01)

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
by: Jing Liu, et al.
Published: (2022-01-01)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
by: Shi M, et al.
Published: (2019-09-01)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
by: Jake Shortt, et al.
Published: (2023-08-01)

P517: PROSPECTIVE MULTICENTRIC STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME IN 230 UNFIT AML PATIENTS TREATED IN FIRST-LINE WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX.
by: A. Candoni, et al.
Published: (2022-06-01)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
by: Inna Shaforostova, et al.
Published: (2023-08-01)

Radiation therapy for early Dupuytren's disease: Interventional procedures guidance [IPG573]
by: National Institute for Health and Care Excellence, CA, et al.
Published: (2016)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
by: Jinye Zhu, et al.
Published: (2023-10-01)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
by: Amer M. Zeidan, et al.
Published: (2023-08-01)